Abstract:Article23 January 2020free access UHMK1 promotes gastric cancer progression through reprogramming nucleotide metabolism Xing Feng orcid.org/0000-0001-8226-3389 The Affiliated Hospital of Guilin Medical University, Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guangxi Neurological Diseases Clinical Research Center, Guilin, Guangxi, China Department of Immuobiology, Yale University School of Medicine, New Haven, CT, USA Search for more papers by this author Dong Ma Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China Search for more papers by this author Jiabao Zhao Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Yongxi Song Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, China Search for more papers by this author Yuekun Zhu Medical Center, Duke University, Durham, NC, USA Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China Search for more papers by this author Qingxin Zhou Department of Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin, China Search for more papers by this author Fei Ma Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China Search for more papers by this author Xing Liu Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China Search for more papers by this author Mengya Zhong Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Yu Liu Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Yubo Xiong Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Xingfeng Qiu Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Zhen Zhang Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Anhui, China Search for more papers by this author Heng Zhang Department of Histology and Embryology, Xiang Ya School of Medicine, Central South University, Changsha, China Search for more papers by this author Yongxiang Zhao National Center for International Research of Biological Targeting Diagnosis and Therapy (Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research), Guangxi Medical University, Nanning, China Search for more papers by this author Kaiguang Zhang Corresponding Author [email protected] orcid.org/0000-0001-9462-6335 Department of Digestive Disease, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, University of Science and Technology of China, Anhui, China Search for more papers by this author Xuehui Hong Corresponding Author [email protected] [email protected] orcid.org/0000-0002-8853-7384 Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Zhiyong Zhang Corresponding Author [email protected] [email protected] orcid.org/0000-0003-4061-7374 The Affiliated Hospital of Guilin Medical University, Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guangxi Neurological Diseases Clinical Research Center, Guilin, Guangxi, China Department of Surgery, Robert-Wood-Johnson Medical School University Hospital, Rutgers University, The State University of New Jersey, New Brunswick, NJ, USA Search for more papers by this author Xing Feng orcid.org/0000-0001-8226-3389 The Affiliated Hospital of Guilin Medical University, Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guangxi Neurological Diseases Clinical Research Center, Guilin, Guangxi, China Department of Immuobiology, Yale University School of Medicine, New Haven, CT, USA Search for more papers by this author Dong Ma Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China Search for more papers by this author Jiabao Zhao Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Yongxi Song Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, China Search for more papers by this author Yuekun Zhu Medical Center, Duke University, Durham, NC, USA Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China Search for more papers by this author Qingxin Zhou Department of Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin, China Search for more papers by this author Fei Ma Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China Search for more papers by this author Xing Liu Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China Search for more papers by this author Mengya Zhong Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Yu Liu Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Yubo Xiong Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Xingfeng Qiu Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Zhen Zhang Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Anhui, China Search for more papers by this author Heng Zhang Department of Histology and Embryology, Xiang Ya School of Medicine, Central South University, Changsha, China Search for more papers by this author Yongxiang Zhao National Center for International Research of Biological Targeting Diagnosis and Therapy (Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research), Guangxi Medical University, Nanning, China Search for more papers by this author Kaiguang Zhang Corresponding Author [email protected] orcid.org/0000-0001-9462-6335 Department of Digestive Disease, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, University of Science and Technology of China, Anhui, China Search for more papers by this author Xuehui Hong Corresponding Author [email protected] [email protected] orcid.org/0000-0002-8853-7384 Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Zhiyong Zhang Corresponding Author [email protected] [email protected] orcid.org/0000-0003-4061-7374 The Affiliated Hospital of Guilin Medical University, Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guangxi Neurological Diseases Clinical Research Center, Guilin, Guangxi, China Department of Surgery, Robert-Wood-Johnson Medical School University Hospital, Rutgers University, The State University of New Jersey, New Brunswick, NJ, USA Search for more papers by this author Author Information Xing Feng1,2,‡, Dong Ma3,‡, Jiabao Zhao4,‡, Yongxi Song5,‡, Yuekun Zhu6,7, Qingxin Zhou8, Fei Ma9, Xing Liu10, Mengya Zhong4, Yu Liu4, Yubo Xiong4, Xingfeng Qiu4, Zhen Zhang11, Heng Zhang12, Yongxiang Zhao13, Kaiguang Zhang *,14, Xuehui Hong *,*,4,‡ and Zhiyong Zhang *,*,1,15,‡ 1The Affiliated Hospital of Guilin Medical University, Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guangxi Neurological Diseases Clinical Research Center, Guilin, Guangxi, China 2Department of Immuobiology, Yale University School of Medicine, New Haven, CT, USA 3Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China 4Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China 5Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, China 6Medical Center, Duke University, Durham, NC, USA 7Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China 8Department of Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin, China 9Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China 10Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China 11Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Anhui, China 12Department of Histology and Embryology, Xiang Ya School of Medicine, Central South University, Changsha, China 13National Center for International Research of Biological Targeting Diagnosis and Therapy (Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research), Guangxi Medical University, Nanning, China 14Department of Digestive Disease, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, University of Science and Technology of China, Anhui, China 15Department of Surgery, Robert-Wood-Johnson Medical School University Hospital, Rutgers University, The State University of New Jersey, New Brunswick, NJ, USA ‡These authors contributed equally to this work ‡These authors contributed equally to this work as senior authors *Corresponding author. Tel: +86 551 62283114; Fax: +86 551 62283114; E-mail: [email protected] *Corresponding author. Tel: +86 592 2993182; Fax: +86 592 2993182; E-mails: [email protected]; [email protected] *Corresponding author. Tel: +1 732 2356853; Fax: +1 732 2356853; E-mails: [email protected]; [email protected] EMBO J (2020)39:e102541https://doi.org/10.15252/embj.2019102541 PDFDownload PDF of article text and main figures. Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info Abstract UHMK1 is a nuclear serine/threonine kinase recently implicated in carcinogenesis. However, the functions and action mechanisms of UHMK1 in the pathogenesis of human gastric cancer (GC) are unclear. Here, we observed that UHMK1 was markedly upregulated in GC. UHMK1 silencing strongly inhibited GC aggressiveness. Interestingly, UHMK1-induced GC progression was mediated primarily via enhancing de novo purine synthesis because inhibiting purine synthesis reversed the effects of UHMK1 overexpression. Mechanistically, UHMK1 activated ATF4, an important transcription factor in nucleotide synthesis, by phosphorylating NCOA3 at Ser (S) 1062 and Thr (T) 1067. This event significantly enhanced the binding of NCOA3 to ATF4 and the expression of purine metabolism-associated target genes. Conversely, deficient phosphorylation of NCOA3 at S1062/T1067 significantly abrogated the function of UHMK1 in GC development. Clinically, Helicobacter pylori and GC-associated UHMK1 mutation induced NCOA3-S1062/T1067 phosphorylation and enhanced the activity of ATF4 and UHMK1. Importantly, the level of UHMK1 was significantly correlated with the level of phospho-NCOA3 (S1062/T1067) in human GC specimens. Collectively, these results show that the UHMK1-activated de novo purine synthesis pathway significantly promotes GC development. Synopsis This study delineates a new role for the nuclear serine/threonine kinase UHMK1 as driver of gastric cancer (GC) via regulating purine metabolism and NCOA3/ATF4-mediated gene expression control. Levels of UHMK1 and NCOA3 phosphorylation are promising stratifiers for patient outcome. UHMK1 expression is significantly upregulated in GC and correlates with poor clinical outcome. UHMK1 directly phosphorylates NCOA3 at Ser1062 and Thr1067 residues. NCOA3-S1062/T1067 phosphorylation promotes ATF4 binding, expression of purine metabolic target genes, and GC progression. Helicobacter pylori infection and GC-related UHMK1 mutation (M134T and T217K) enhance NCOA3-S1062/T1067 phosphorylation, activity of ATF4 and UHMK1. Introduction Gastric cancer (GC) has been indicated to be one of the deadliest malignancies. Helicobacter pylori (H. pylori) infection, dietary habits, and other environmental risk agents contribute greatly to GC development (Wroblewski et al, 2010). Although surgical resection is a primary therapeutic option for GC patients, the 5-year survival rate remains approximately 30.6% but is only 5.2% for patients with advanced stages (Yusefi et al, 2018). Therefore, a better understanding of molecular aberrations involved in GC pathogenesis is necessary to improve the clinical outcomes of GC patients. U2AF homology motif kinase 1 (UHMK1) is a ubiquitously expressed nuclear serine (Ser, S)/threonine (Thr, T) kinase (Francone et al, 2010). It was initially identified to regulate the function of stathmin (Barbutti et al, 2017). Since then, UHMK1 has been indicated to bind a range of proteins, such as eEF1A, FAM64, cyclin-dependent kinase inhibitor (CDKI), p27KIP1, SF3b155, and CPEB1, suggesting the varied roles of UHMK1 in different cellular processes (Manceau et al, 2008; Cambray et al, 2009). Although UHMK1 dysregulation or mutation has been recently indicated to be a high-penetrant factor in different types of human tumors, such as pancreatic and ovarian cancer (Katchman et al, 2017; Grant et al, 2018; Wang et al, 2018), its effect and action mechanisms in most cancers including GC still were uncovered. Tumor cells reprogram glucose metabolism by switching from oxidative phosphorylation (OXPHOS) to a process termed the Warburg effect (Song et al, 2014). However, emerging evidence indicates that dysregulated purine metabolism is implicated in tumors (Nishimura et al, 2019). This finding is not surprising, because many metabolites from the Warburg effect or pentose phosphate pathway (PPP) are essential carbon sources for purine biosynthesis (Hong et al, 2014). Several kinases and transcription factors (TFs), for example, mechanistic target of rapamycin kinase (mTOR), activating transcription factor 4 (ATF4), microphthalmia-associated transcription factor (MITF), and c-Myc, dictate cancer-dependent purine biosynthesis (Ben-Sahra et al, 2016; Karigane et al, 2016). We recently reported that dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 3 (Dyrk3) inhibited liver cancer by downregulating purine synthesis (Ma et al, 2019). However, the effect of purine metabolism on GC is not clear. Herein, by analyzing data from The Cancer Genome Atlas (TCGA) and Oncomine database, we found that genomic DNA of UHMK1 was frequently amplified in GC. Therefore, we further investigated the role and mechanism of UHMK1 in GC. We found that upregulation of UHMK1 suggested poor prognosis of GC patients. We demonstrated that UHMK1 functioned as an oncogene mainly by promoting the purine synthesis pathway in GC. Therefore, UHMK1-enhanced nucleotide synthesis might be an important therapeutic target in GC. Results High-level UHMK1 expression is strongly correlated with GC aggressiveness We first examined the functions of UHMK1 in GC by investigating the relative levels of UHMK1 in five paired GC patient tissues and corresponding normal tissues. The amount of UHMK1 was significantly increased in GC tissues compared with control tissues (Fig 1A). In addition, the amount of UHMK1 in most GC cell lines was often higher than that in the GES-1 cell line, a normal gastric epithelial cell line (Fig 1B). Similar results were found in other studies of GC in TCGA and Oncomine datasets (Fig EV1A–F). The tissue array analysis results indicated that compared to normal tissues, GC tissues presented increased expression levels of UHMK1 (Fig 1C) and that the percentage of cells with UHMK1 expression in patients with stage I, II, III, and IV GC was 18.2, 36.4, 69, and 100, respectively (Fig 1D), further implying that the level of UHMK1 is strongly correlated with GC malignancy. Analysis of 100 patients with GC confirmed that the level of UHMK1 was strongly associated with tumor status, stage, and lymph node metastasis (Fig 1E and Appendix Table S1). Kaplan–Meier analysis of two independent cohorts indicated that GC patients with higher amounts of UHMK1 presented shorter disease-free survival (DFS) and overall survival (OS) times (Figs 1F and EV1G and H). Multivariate analyses identified UHMK1 as an independent prognostic factor in GC (Appendix Table S2). Collectively, our data reveal that UHMK1 may promote the pathogenesis of GC. Figure 1. High expression of UHMK1 predicts poor prognosis of GC patients A. UHMK1 levels in tumor tissues (T) and corresponding nontumor tissues (N) from five GC patients were analyzed using Western blotting and qRT–PCR. The relative mRNA expression of UHMK1 was presented as mean ± standard deviation from three replicates. Pairwise two-tailed statistical significance was assessed by Student's t-test. B. Immunoblotting and qRT–PCR were used to measure the levels of UHMK1 in GES-1 and GC cell lines. The relative mRNA expression of UHMK1 was presented as mean ± standard deviation from three replicates. Pairwise two-tailed statistical significance was assessed by Student's t-test. C. IHC analysis of UHMK1 expression in a GC patient tissue array (n = 102). Representative images are shown. Scale bars = 100 μm. D. The IHC signals were scored using the Allred score as described in Material and Methods. Data were shown as mean ± standard deviation from three independent experiments. E. UHMK1 expression in 100 GC patients was analyzed based on the following parameters: tumor stage, tumor status, and lymph node invasion status. Fisher's test was applied to calculate the exact P value. F. Patients with GC were stratified by the UHMK1 level (n = 100); OS and DFS were assessed by Kaplan–Meier analysis. Data information: *P < 0.05, **P < 0.01, ***P < 0.001. Download figure Download PowerPoint Click here to expand this figure. Figure EV1. TCGA and Oncomine analysis of UHMK1 expression in GC patients A. TCGA analyzing the levels of UHMK1 in GC patients. *P < 0.05. The central line stands for the median expression of UHMK1. Upper line stands for upper limit (Upper quartile +1.5 interquartile range). Lower line stands for lower limit (lower quartile –1.5 interquartile range). B–F. Analysis of UHMK1 expression from Oncomine database. The central line stands for the median expression of UHMK1. Upper line stands for upper limit (Upper quartile +1.5 interquartile range). Lower line stands for lower limit (lower quartile –1.5 interquartile range) (three biological replicates). G, H. Kaplan–Meier analysis from the second independent cohort of GC patients indicated that patients with higher levels of UHMK1 had shorter OS (G) and DFS (H). Survival curves were plotted according to Kaplan–Meier method, with the log-rank test applied for comparison. Download figure Download PowerPoint UHMK1 knockdown strongly inhibits the proliferation and invasion of GC cells, possibly via metabolic pathway reprogramming To elucidate the functions of UHMK1 in GC, three lentivirus-mediated UHMK1-specific short hairpin RNAs (shRNAs) were transfected to knock down endogenous UHMK1 in two GC cell lines. shUHMK1-#1 and shUHMK1-#2, with high inhibition rates, were selected for further experiments (Fig 2A). UHMK1 deficiency significantly reduced GC cell proliferation, colony formation, migration, and invasion relative to the corresponding levels in negative control cells (Figs 2B and C, and EV2A–F). However, reintroduction of a shRNA-resistant UHMK1 construct, UHMK1Δ, significantly reversed these phenotypes in SGC7901-shUHMK1-#1 or MGC803-shUHMK1-#1 cells (Figs 2B and C, and EV2A–F). Consistent with this result, UHMK1 overexpression in BGC823 and HGC27 cells markedly promoted their proliferative and invasive abilities (Fig EV2G–M). Figure 2. UHMK1 knockdown strongly suppresses the proliferative and invasive abilities of GC cells, possibly via metabolic pathway reprogramming A–C. (A) GC cells (SGC7901 and MGC803) were transfected with (A) shUHMK1-#1, shUHMK1-#2, shUHMK1-#3, or control shRNA lentiviral vector or (B) with a shRNA-resistant expression construct, UHMK1Δ. Western blotting was used to measure the levels of UHMK1. NIH ImageJ software was used to quantify the band intensity. Western blotting assay was conducted for three replicates. (B and C) SGC7901 cells were transfected with or without shUHMK1-#1 or the shRNA-resistant expression construct UHMK1Δ. CCK-8 and colony formation assays were conducted. Scale bars = 5 mm. D, E. The volumes of subcutaneous gastric tumors derived from SGC7901 cells in NOD/SCID mice were determined at different time points. Tumors and representative bioluminescence images are also shown. UHMK1 silencing in the mouse model was confirmed by Western blotting (three biological replicates). Data were presented as mean ± standard deviation from shcontrol and shUHMK1-#1 mice (n = 10 mice/group). Unpaired two-tailed statistical significance was assessed by Student's t-test. Scale bars = 1 cm. F, G. UHMK1 silencing (F) and overexpression (G) affected GC cell abdominal metastasis. The quantitative number of metastatic nodules (left panel) in nude mice (n = 10 mice/group). Representative images of abdominal metastases are also shown (right panel). Scale bars = 1 cm. H. Heatmap of the top 500 genes upregulated in GC patients with high UHMK1 expression. I. Gene ontology enrichment analysis was used to analyze the top 20 enriched biological processes among GC patients with high UHMK1 expression. Data information: **P < 0.01, ***P < 0.001, # marked no significance. Download figure Download PowerPoint Click here to expand this figure. Figure EV2. UHMK1 knockdown strongly suppresses GC cell proliferation and invasion A, B. SGC7901 cells were infected with or without shUHMK1-#1, or a shRNA-resistant expression construct, UHMK1Δ. We performed Transwell assays to measure GC cell migration and invasion, respectively. (Left panel) The quantitative number of migrated or invaded cells in shcontrol, shUHMK1-#1, shUHMK1-#1+Vector, and shUHMK1-#1+UHMK1Δ group. Data were presented as mean ± standard deviation from three replicates. Two-tailed statistical significance was assessed by Student's t-test. (Right panel) Representative images of migrated or invaded cells in each group are shown. Scale bars = 100 μm. C. MGC803 cells were transfected with or without shUHMK1-#1, or UHMK1Δ. CCK-8 assay was conducted to explore the biological function of UHMK1 on cell growth. The growth rate was evaluated from Day 1 to Day 6. Data were presented as mean ± standard deviation from three replicates. Two-tailed statistical significance was assessed by Student's t-test. D–F. MGC803 cells were transfected with or without shUHMK1-#1 or UHMK1Δ. Colony formation and Transwell assays were used to measure GC cell proliferation, invasion, and migration, respectively. (Left panel) The quantitative number of colonies, migrated or invaded cells in shcontrol, shUHMK1-#1, shUHMK1-#1+Vector, and shUHMK1-#1+UHMK1Δ group. Data were presented as mean ± standard deviation from three replicates. (Right panel) Representative images of colonies, migrated or invaded cells in each group are shown. Scale bars = 100 μm. G. Western blotting was performed to analyze UHMK1 expression in BGC823 cells transfected with or without UHMK1. CCK-8 assay was conducted to explore the biological function of UHMK1 on cell growth. The growth rate was evaluated from Day 1 to Day 6. Data were presented as mean ± standard deviation from three replicates. Two-tailed statistical significance was assessed by Student's t-test. H, I. BGC823 cells were transfected with or without UHMK1. Colony formation and Transwell assays were used to measure GC cell proliferation, invasion, and migration, respectively. (Left panel) The quantitative number of colonies, migrated or invaded cells in Vector and UHMK1 group. Data were presented as mean ± standard deviation from three replicates. (Right panel) Representative images of colonies, migrated or invaded cells in each group are shown. Scale bars = 100 μm. J. Western blotting was performed to analyze UHMK1 expression in HGC27 cells transfected with or without UHMK1. CCK-8 assay was conducted to explore the biological function of UHMK1 on cell growth. The growth rate was evaluated from Day 1 to Day 6. Data were presented as mean ± standard deviation from three replicates. Two-tailed statistical significance was assessed by Student's t-test. K–M. HGC27 cells were transfected with or without UHMK1. Colony formation and Transwell assays were used to measure GC cell proliferation, invasion, and migration, respectively. (Left panel) The quantitative number of colonies, migrated or invaded cells in Vector and UHMK1 group. Data were presented as mean ± standard deviation from three replicates. (Right panel) Representative images of colonies, migrated or invaded cells in each group are shown. Scale bars = 100 μm. N. NOD/SCID mice (n = 10 per group) were injected subcutaneously with 1.5 × 106 BGC823-vector and BGC823-UHMK1 into opposite flanks. At indicated time points, the xenograft tumors were collected and presented. Scale bars = 5 mm. Data information: Unpaired two-tailed statistical significance was assessed by Student's t-test. *P < 0.05, **P < 0.01, ***P < 0.001, # marked no significance. Download figure Download PowerPoint In vivo, knockdown of UHMK1 significantly decreased GC tumorigenesis and the number of abdominal metastatic nodules compared to these parameters in control mice (Fig 2D–F). However, UHMK1 overexpression significantly promoted GC growth and increased the number of metastatic nodules (Figs EV2N and 2G). To further uncover the function of UHMK1 in GC, we assessed the transcriptomes of GC patients in TCGA with varying levels of UHMK1 expression. And the top 500 differentially expressed genes were analyzed in UHMK1high versus UHMK1low patients (Fig 2H and Appendix Table S3). Gene ontology enrichment analysis indicated that high UHMK1 expression in GC patients might be associated mainly with tumor metabolism (Fig 2I). In summary, UHMK1 upregulation significantly promotes GC growth and metastasis possibly via metabolic pathway reprogramming in tumors. UHMK1 upregulation promotes the invasion and proliferation of GC cells by promoting the de novo purine synthesis pathway To examine whether UHMK1 reprograms GC-associated metabolic pathways, mass spectrometry (MS) was performed to assemble the collect metabolic profiles of SGC7901 cells with or without UHMK1 knockdown. Interestingly, UHMK1 silencing significantly reduced the intracellular pools of purine intermediates and a moderate decrease in pyrimidine metabolites (Appendix Table S4 and Fig 3A and B). Thus, silencing UHMK1 in GC cells primarily inhibits purine biosynthesis. Figure 3. UHMK1 upregulation significantly increases the proliferative and invasive abilities of GC cells by reprogramming purine metabolism A. Schematic representation of the main metabolic pathways. B. LC-MS/MS was used to examine the metabolites in SGC7901 cells with or without UHMK1 knockdown. The data are shown in the heatmap. C. (Upper panel) LC-MS/MS analysis was performed to measure 15N-glutamine-labeled purine synthesis intermediates in BGC823 cells transfected with or without the WT-UHMK1 or UHMK1-K54R constructs. (Lower panel) LC-MS/MS was used to analyze metabolites labeled with 13C-glycine in BGC823 cells transfected with or without the WT-UHMK1 or UHMK1-K54R constructs (three biological replicates). D. RNA and DNA with incorporated 14C-glycine in BGC823 cells transfected with or without the WT-UHMK1 or UHMK1-K54R constructs were examined using LC-MS/MS (three biological replicates). E. qRT–PCR assays were used to analyze the effects of WT-UHMK1 or UHMK1-K54R on the genes controlling purine metabolism. Data were presented as mean ± standard deviation from three replicates. Unpaired two-tailed statistical significance was assessed by Student's t-test. F. UHMK1 silencing significantly decreased SGC7901 cell proliferation, while ATIC overexpression or purine supplementation markedly reversed this inhibition. Data were presented as mean ± standard deviation from three replicates. Unpaired two-tailed statistical significance was assessed by Student's t-test. G. Treatment with the ATIC inhibitor significantly reversed the proliferation of BGC823 cells induced by UHMK1 overexpression. Data were presented as mean ± standard deviation from three replicates. Unpaired two-tailed statistical significance was assessed by Student's t-test. Data information: *P < 0.05, **P < 0.01, ***P < 0.001, # marked no significance. Download figure Download PowerPoint We then used stable isotope-labeled glutamine (amide-15N) to investigate the effect of UHMK1 on purine metabolism (Dayie & Thakur, 2010). Overexpression of wild-type (WT) UHMK1 but not the kinase-dead UHMK1-K54R mutant in BGC823 cells obviously increased the amounts of 15N-purine intermediates (IMP, AMP, and GMP) (Fig 3C upper panel), suggesting that the kinase activity o

Abstract:Cancer CommunicationsEarly View LETTER TO THE EDITOROpen Access Transcriptome-wide association analysis identified candidate susceptibility genes for nasopharyngeal carcinoma Yong-Qiao He, Yong-Qiao He State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorWen-Qiong Xue, Wen-Qiong Xue State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorDan-Hua Li, Dan-Hua Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorTong-Min Wang, Tong-Min Wang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorZhi-Ming Mai, Zhi-Ming Mai School of Public Health, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Center for Nasopharyngeal Carcinoma Research, Research Grants Council Area of Excellence Scheme, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892 USASearch for more papers by this authorDa-Wei Yang, Da-Wei Yang School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorChang-Mi Deng, Chang-Mi Deng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorYing Liao, Ying Liao State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorWen-Li Zhang, Wen-Li Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorRuo-Wen Xiao, Ruo-Wen Xiao State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorLuting Luo, Luting Luo School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorHua Diao, Hua Diao School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorXiating Tong, Xiating Tong School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorYanxia Wu, Yanxia Wu State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorJiang-Bo Zhang, Jiang-Bo Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorTing Zhou, Ting Zhou orcid.org/0000-0003-4349-2036 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorXi-Zhao Li, Xi-Zhao Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorPei-Fen Zhang, Pei-Fen Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorXiao-Hui Zheng, Xiao-Hui Zheng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorShao-Dan Zhang, Shao-Dan Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorYe-Zhu Hu, Ye-Zhu Hu State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorMinzhong Tang, Minzhong Tang Wuzhou Red Cross Hospital, Wuzhou, Guangxi, 543002 P. R. China Wuzhou Cancer Center, Wuzhou, Guangxi, 543002 P. R. ChinaSearch for more papers by this authorYuming Zheng, Yuming Zheng Wuzhou Red Cross Hospital, Wuzhou, Guangxi, 543002 P. R. China Wuzhou Cancer Center, Wuzhou, Guangxi, 543002 P. R. ChinaSearch for more papers by this authorYonglin Cai, Yonglin Cai Wuzhou Red Cross Hospital, Wuzhou, Guangxi, 543002 P. R. China Wuzhou Cancer Center, Wuzhou, Guangxi, 543002 P. R. ChinaSearch for more papers by this authorEllen T. Chang, Ellen T. Chang Center for Health Sciences, Exponent, Inc., Menlo Park, CA, 94025, Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, 94143 USASearch for more papers by this authorZhe Zhang, Zhe Zhang Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021 P. R. ChinaSearch for more papers by this authorGuangwu Huang, Guangwu Huang Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021 P. R. ChinaSearch for more papers by this authorSu-Mei Cao, Su-Mei Cao State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorQing Liu, Qing Liu State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorLin Feng, Lin Feng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorYing Sun, Ying Sun orcid.org/0000-0002-5888-2929 Department of Radiation Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorMaria Li Lung, Maria Li Lung Center for Nasopharyngeal Carcinoma Research, Research Grants Council Area of Excellence Scheme, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Department of Clinical Oncology, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. ChinaSearch for more papers by this authorHans-Olov Adami, Hans-Olov Adami Clinical Effectiveness Group, Institute of Health and Society, University of Oslo, Oslo, 0316 Norway Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, 17177 SwedenSearch for more papers by this authorWeimin Ye, Weimin Ye Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, 17177 Sweden Department of Epidemiology and Health Statistics & Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian, 350122 P. R. ChinaSearch for more papers by this authorTai-Hing Lam, Tai-Hing Lam School of Public Health, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Center for Nasopharyngeal Carcinoma Research, Research Grants Council Area of Excellence Scheme, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. ChinaSearch for more papers by this authorWei-Hua Jia, Corresponding Author Wei-Hua Jia jiawh@sysucc.org.cn orcid.org/0000-0002-0528-8715 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. China School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. China Correspondence Wei-Hua Jia, M.D., Ph.D. Professor, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dong Feng East Road, Guangzhou 510060, Guangdong, P. R. China. Email: jiawh@sysucc.org.cnSearch for more papers by this author Yong-Qiao He, Yong-Qiao He State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorWen-Qiong Xue, Wen-Qiong Xue State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorDan-Hua Li, Dan-Hua Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorTong-Min Wang, Tong-Min Wang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorZhi-Ming Mai, Zhi-Ming Mai School of Public Health, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Center for Nasopharyngeal Carcinoma Research, Research Grants Council Area of Excellence Scheme, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, 20892 USASearch for more papers by this authorDa-Wei Yang, Da-Wei Yang School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorChang-Mi Deng, Chang-Mi Deng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorYing Liao, Ying Liao State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorWen-Li Zhang, Wen-Li Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorRuo-Wen Xiao, Ruo-Wen Xiao State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorLuting Luo, Luting Luo School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorHua Diao, Hua Diao School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorXiating Tong, Xiating Tong School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. ChinaSearch for more papers by this authorYanxia Wu, Yanxia Wu State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorJiang-Bo Zhang, Jiang-Bo Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorTing Zhou, Ting Zhou orcid.org/0000-0003-4349-2036 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorXi-Zhao Li, Xi-Zhao Li State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorPei-Fen Zhang, Pei-Fen Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorXiao-Hui Zheng, Xiao-Hui Zheng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorShao-Dan Zhang, Shao-Dan Zhang State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorYe-Zhu Hu, Ye-Zhu Hu State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorMinzhong Tang, Minzhong Tang Wuzhou Red Cross Hospital, Wuzhou, Guangxi, 543002 P. R. China Wuzhou Cancer Center, Wuzhou, Guangxi, 543002 P. R. ChinaSearch for more papers by this authorYuming Zheng, Yuming Zheng Wuzhou Red Cross Hospital, Wuzhou, Guangxi, 543002 P. R. China Wuzhou Cancer Center, Wuzhou, Guangxi, 543002 P. R. ChinaSearch for more papers by this authorYonglin Cai, Yonglin Cai Wuzhou Red Cross Hospital, Wuzhou, Guangxi, 543002 P. R. China Wuzhou Cancer Center, Wuzhou, Guangxi, 543002 P. R. ChinaSearch for more papers by this authorEllen T. Chang, Ellen T. Chang Center for Health Sciences, Exponent, Inc., Menlo Park, CA, 94025, Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, 94143 USASearch for more papers by this authorZhe Zhang, Zhe Zhang Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021 P. R. ChinaSearch for more papers by this authorGuangwu Huang, Guangwu Huang Department of Otolaryngology-Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, 530021 P. R. ChinaSearch for more papers by this authorSu-Mei Cao, Su-Mei Cao State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorQing Liu, Qing Liu State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorLin Feng, Lin Feng State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorYing Sun, Ying Sun orcid.org/0000-0002-5888-2929 Department of Radiation Oncology, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangzhou, Guangdong, 510060 P. R. ChinaSearch for more papers by this authorMaria Li Lung, Maria Li Lung Center for Nasopharyngeal Carcinoma Research, Research Grants Council Area of Excellence Scheme, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Department of Clinical Oncology, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. ChinaSearch for more papers by this authorHans-Olov Adami, Hans-Olov Adami Clinical Effectiveness Group, Institute of Health and Society, University of Oslo, Oslo, 0316 Norway Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, 17177 SwedenSearch for more papers by this authorWeimin Ye, Weimin Ye Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, 17177 Sweden Department of Epidemiology and Health Statistics & Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, Fujian, 350122 P. R. ChinaSearch for more papers by this authorTai-Hing Lam, Tai-Hing Lam School of Public Health, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. China Center for Nasopharyngeal Carcinoma Research, Research Grants Council Area of Excellence Scheme, The University of Hong Kong, Hong Kong S.A.R., 999077 P. R. ChinaSearch for more papers by this authorWei-Hua Jia, Corresponding Author Wei-Hua Jia jiawh@sysucc.org.cn orcid.org/0000-0002-0528-8715 State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060 P. R. China School of Public Health, Sun Yat-sen University, Guangzhou, Guangdong, 510080 P. R. China Correspondence Wei-Hua Jia, M.D., Ph.D. Professor, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, 651 Dong Feng East Road, Guangzhou 510060, Guangdong, P. R. China. Email: jiawh@sysucc.org.cnSearch for more papers by this author First published: 01 June 2022 https://doi.org/10.1002/cac2.12317 Yong-Qiao He, Wen-Qiong Xue, Dan-Hua Li, and Tong-Min Wang have contributed equally to this work. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abbreviations EBV Epstein-Barr virus GO gene ontology GWAS genome-wide association analysis HBV hepatitis B virus HCV hepatitis C virus HLA human leukocyte antigen KEGG Kyoto encyclopedia of genes and genomes LD linkage disequilibrium NPC nasopharyngeal carcinoma PIP posterior inclusion probability QC quality control TWAS transcriptome-wide association analysis ZEBRA BamHI Z EBV replication activator Dear Editor, Nasopharyngeal carcinoma (NPC) is a common malignancy in East and Southeast Asia, especially in South China. The etiology of NPC has been linked to genetic susceptibility, Epstein-Barr virus (EBV) infection, and environmental factors. Accumulated evidence including multiple genome-wide association studies (GWASs) has revealed robust genetic predisposition of NPC. However, GWAS-identified genetic variants collectively account for only 8.2% of NPC heritability [1]. The underlying inherited predisposition is largely undetermined. The strongest genetic signal for NPC consistently hits the human leukocyte antigen (HLA) region on 6p21 [2]. However, the highly polymorphic nature and complicated long-range linkage disequilibrium (LD) in the HLA region particularly obscure the causal variants driving the association. In addition, most genetic variants located in introns or intergenic regions. The causal genes mediating genetic effects on NPC risk have rarely been ascertained by GWAS alone. Recently, transcriptome-wide association study (TWAS) has been proposed as an attractive approach to identify novel gene-trait associations and prioritize causal genes for complex traits [3]. By integrating GWAS and gene expression data, TWAS can effectively and economically assess associations between genetically predicted gene expression levels and disease risks in large populations. Hence, using the cis-regulated expression in addition to genetic variants to explore NPC susceptibility genes could be promising and reasonable for mechanistic and functional inference. Nevertheless, neither public data of nasopharyngeal tissue were available, nor TWAS for NPC had been conducted. Herein, we integrated genome and transcriptome data of 89 nasopharyngeal tumor tissues and investigated the associations between predicted gene expression levels and NPC risk using multicenter GWAS data involving 4506 NPC cases and 5384 cancer-free subjects (defined as controls) from South China. Given the close relationship between EBV infection and NPC, a cis-regulated expression weight matrix from EBV-transformed lymphocytes (n = 117) in the GTEx project was used for further evaluation. Study populations and detailed methodology are described in the Supplementary file of methods. We predicted the expression levels of 2505 and 2411 genes in the GWAS population by constructing the models for the prediction of gene expression in nasopharyngeal tissues (NP models) and EBV-transformed lymphocytes (lymphocyte models), respectively (Supplementary Table S1), and 377 genes overlapped (Supplementary Figure S1). Thirty-three genes were associated with NPC at a Bonferroni-corrected threshold, and all were located in the HLA region (Figure 1A). Among them, 11 of 13 previously reported genes were replicated. Our results were consistent with the studies focusing on the HLA region in South China [4, 5], where most of the reported genes available in TWAS were replicated. The predicted expression levels of ZFP57 (NP models), MICA (both models), and HLA-C (lymphocyte models) were significantly higher in cases than in controls, while the expression levels of MOG, HCG27, HLA-DQB1, HLA-H, HLA-U (NP models), HLA-F (both models), HLA-A, and HLA-DRB1 (lymphocyte models) were lower in cases than in controls. The two overlapping genes showed similar associations with NPC (HLA-F: Z score = -10.28 and -8.95; MICA: Z score = 7.82 and 6.60, for NP and lymphocyte models, respectively) (Supplementary Table S2). Interestingly, half of the previously reported genes belonged to HLA class I. Most of them showed lower levels of predicted expression in cases than in controls, possibly because EBV transcripts in NPC tumors were involved in the inhibition of HLA class I gene expression [6]. It is rational to assume that the low expression levels of these genes may affect the anti-EBV immune response in presenting peptides to cytotoxic T cells, facilitating immune evasion of tumor cells or EBV-mediated oncogenic action. FIGURE 1Open in figure viewer TWAS-identified susceptibility genes and pathways for NPC. (A) Manhattan plot of TWAS in NP models and lymphocyte models. The blue lines represent the Bonferroni-corrected significance threshold. The red dots above or below the blue line represent the genes passed the Bonferroni threshold in the association analysis. The genes with green labels have been reported to be associated with NPC by previous genome-wide or candidate pathway association studies. The genes with black labels were newly identified as NPC susceptibility genes by our study. The genes in different chromosomes were exhibited in light and dark grey dots. (B) Expression quantitative trait locus analysis for the seven putative causal genes in the expression data of 89 nasopharyngeal tissue samples. The Kruskal-Wallis test was used to compare medians among three genotypes for most of the variants. In a certain homozygote group, the P values were recalculated using only the wild-type and heterozygous groups for the expression of MICD, HCG27 and HLA-DOB by excluding the groups with a sample size less than 5. (C) GO pathway enrichment analysis of NPC. (D) KEGG pathway enrichment analysis of NPC. “Gene Ratio” refers to the percentage of total significant genes in the given pathway. All 354 significant genes (P < 0.05) in TWAS were used in the enrichment analysis. Abbreviations: TWAS, Transcriptome-wide association analysis; NPC, Nasopharyngeal carcinoma; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes Although the significant signals consistently hit the HLA region, 22 additional genes not previously reported were identified in TWAS. Among them, the predicted expression levels of 9 genes were significantly higher in NPC cases than in controls, including HLA-DOB, HCG4B, RPL23AP1, HLA-J in NP models and HCG4, CCHCR1, STK19, C4B, IFITM4P in lymphocyte models, while 13 other genes showed significantly lower expression levels in cases than in controls, including HCP5, ZSCAN23, HCG4P11, HCG4P7, MICD, MICB-DT, SNHG32 in NP models and NOTCH4, C4A, HCG22, POU5F1, MICE, HLA-S in lymphocyte models (Figure 1A). We performed conditional analyses to determine whether the associations between predicted gene expression levels and NPC were influenced by the GWAS signals. After conditioning on the respective GWAS index SNP, the associations for HLA-DOB, NOTCH4, ZSCAN23, STK19, C4B, HLA-J, HLA-S, and MICB-DT remained significant. After conditioning on all previously reported SNPs, NOTCH4, HCG4, HCG22, POU5F1, HCG4B, HCG4P11, MICB-DT, STK19 and IFITM4P remained significant. It indicated that their associations were partially independent of the GWAS signals (Supplementary Table S3). Due to the complicated structure with high LD and co-expression networks in the HLA region, we conducted fine-mapping analyses to prioritize the causal genes. Using posterior inclusion probability (PIP) analysis, we prioritized 7 causal genes: MICA, HLA-DQB1, HLA-DOB, ZSCAN23, HCG27, MICD, and HLA-U. HLA-DOB, ZSCAN23, and MICD were newly identified as NPC susceptibility genes (Supplementary Table S4). Furthermore, we conducted expression quantitative trait locus (eQTL) analyses to identify whether the genetic variants could influence the expression levels of these genes. We found that individuals with relevant risk SNPs (the GWAS index SNPs) exhibited higher expression of HLA-DQB1, MICA, MICD and HLA-U, or lower expression levels of ZSCAN23, HCG27, and HLA-DOB. These results indicated that the risk alleles affected the expression levels of the causal genes (Figure 1B). Two HLA class II genes (HLA-DQB1 and HLA-DOB) were prioritized as causal genes. Both genes were associated with other virus-associated cancers, such as cervical cancer [7]. A comprehensive TWAS exploring genetic susceptibility for antiviral immune response using 7924 subjects from the UK Biobank cohort revealed that the genetic determinants for EBV infection were predominantly located on HLA class II genes. The most significant signals associated with the antibody level of BamHI Z EBV replication activator (ZEBRA) hit HLA-DQB1 [8]. HLA-DOB may impact viral clearance capacity and persistent infection of hepatitis B virus (HBV) and hepatitis C virus (HCV) [9]. Since EBV reactivation with elevated EBV DNA load or antibodies was observed at the preclinical phase of NPC, we hypothesized that HLA class II genes, especially HLA-DQB1and HLA-DOB, participate in the early stage of NPC tumorigenesis by influencing EBV infection. Besides, some identified pseudogenes, such as IFITM4P [10], may function by regulating their parental genes. However, their biological mechanisms remain unclear, and further researches are needed. Gene Ontology (GO) enrichment analysis confirmed that TWAS-identified genes (354 genes with P < 0.05) were enriched in the pathways of cell-mediated immune response, antigen processing and presentation (Figure 1C). Similarly, the top pathways annotated with the Kyoto Encyclopedia of Genes and Genomes (KEGG) database focused on infection of herpes simplex virus type 1, human T-cell leukemia virus type 1, EBV, and autoimmune disorders such as graft-versus-host disease (Figure 1D). In summary, using a TWAS approach, we corroborated the central role of HLA genes in NPC susceptibility. Apart from HLA class I genes, we propose critical roles of HLA class II genes and other nonclassical HLA genes. Seven genes, including HLA-DQB1 and HLA-DOB, were prioritized as causal genes. Recent evidence indicated that these genes are pivotal in the metastable equilibrium between host and virus. Our findings provide additional evidence for a better understanding of the genetic etiology of NPC and clues to further advance this field. DECLARATIONS ACKNOWLEDGEMENTS We thank the staffs from Sun Yat-sen University Cancer Center biorepository. We thank all the study participants and research staff who recruited participants and collected samples in this study. This study was funded by the National Key Research and Development Program of China (2021YFC2500400), the Basic and Applied Basic Research Foundation of Guangdong Province, China (2021B1515420007), Sino-Sweden Joint Research Programme (81861138006), the Science and Technology Planning Project of Guangzhou, China (201804020094), the Special Support Program for High-level Professionals on Scientific and Technological Innovation of Guangdong Province, China (2014TX01R201), National Natural Science Foundation of China (81973131, 81903395, 81803319, 82003520), National Science Fund for Distinguished Young Scholars of China (81325018). CONFLICT OF INTEREST The authors have no potential conflicts of interest to declare. ETHICS APPROVAL AND CONSENT TO PARTICIPATE The Institutional Review Board of Sun Yat-sen University Cancer Center approved this study. Informed consent was obtained from all study participants. AUTHOR CONTRIBUTIONS WHJ and YQH devised the project and the main conceptual ideas; YQH, WQX, DHL, and TMW wrote the original draft; DHL and TMW performed the computational analyses; TMW, DWY, CMD, and WLZ contributed to implementation of data processing and analyses; DWY, CMD, YL, WLZ, RWX, LL, HD, XT, YW, TZ, XZL, PFZ, XHZ, SDZ, YZH, MT, YZ, YC and JBZ contributed to the sample preparation; TMW and WLZ contributed to the RNA-seq quantification and quality control pipeline; ETC, ZZ, GH, SMC, QL, LF, YS, MLL, HOA, WY, and THL contributed to the interpretation of the results; YQH, WQX, and TMW revised and wrote the final version of the manuscript; verified the analytical methods; WHJ supervised the project. All authors read and approved the final manuscript. AVAILABILITY OF DATA AND MATERIALS Methods and materials are available in the supplementary file. The datasets generated and used during the current study are available at Research Data Deposit (RDD) public platform (www.researchdata.org.cn) with the approval RDD number of RDDB2021406340. Supporting Information Filename Description cac212317-sup-0001-SuppMat.docx136.9 KB Supporting information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Dai J, Shen W, Wen W, Chang J, Wang T, Chen H, et al. Estimation of heritability for nine common cancers using data from genome-wide association studies in Chinese population. Int J Cancer. 2017; 140(2): 329– 36. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar 2Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, Chen LZ, et al. A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet. 2010; 42(7): 599– 603. CrossrefCASPubMedWeb of Science®Google Scholar 3Wainberg M, Sinnott-Armstrong N, Mancuso N, Barbeira AN, Knowles DA, Golan D, et al. Opportunities and challenges for transcriptome-wide association studies. Nat Genet. 2019; 51(4): 592– 9. CrossrefCASPubMedWeb of Science®Google Scholar 4Ning L, Ko JM, Yu VZ, Ng HY, Chan CK, Tao L, et al. Nasopharyngeal carcinoma MHC region deep sequencing identifies HLA and novel non-HLA TRIM31 and TRIM39 loci. Commun Biol. 2020; 3(1): 759. CrossrefCASPubMedWeb of Science®Google Scholar 5Tian W, Zhu F, Cai J, Li L, Jin H, Wang W. Multiple low-frequency and rare HLA-B allelic variants are associated with reduced risk in 1,105 nasopharyngeal carcinoma patients in Hunan province, southern China. Int J Cancer. 2020; 147(5): 1397– 1404. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar 6Sengupta S, den Boon JA, Chen IH, Newton MA, Dahl DB, Chen M, et al. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res. 2006; 66(16): 7999– 8006. CrossrefCASPubMedWeb of Science®Google Scholar 7Peng S, Trimble C, Wu L, Pardoll D, Roden R, Hung CF, et al. HLA-DQB1*02-restricted HPV-16 E7 peptide-specific CD4+ T-cell immune responses correlate with regression of HPV-16-associated high-grade squamous intraepithelial lesions. Clin Cancer Res. 2007; 13(8): 2479– 87. CrossrefCASPubMedWeb of Science®Google Scholar 8Kachuri L, Francis SS, Morrison ML, Wendt GA, Bosse Y, Cavazos TB, et al. The landscape of host genetic factors involved in immune response to common viral infections. Genome Med. 2020; 12(1): 93. CrossrefCASPubMedWeb of Science®Google Scholar 9Denzin LK, Khan AA, Virdis F, Wilks J, Kane M, Beilinson HA, et al. Neutralizing Antibody Responses to Viral Infections Are Linked to the Non-classical MHC Class II Gene H2-Ob. Immunity. 2017. 47(2): 310– 22 e7. CrossrefCASPubMedWeb of Science®Google Scholar 10Xiao M, Chen Y, Wang S, Liu S, Rai KR, Chen B, et al. LncRNA IFITM4P regulates host antiviral responses by acting as a ceRNA. J Virol. 2021;JVI0027721. CrossrefGoogle Scholar Early ViewOnline Version of Record before inclusion in an issue FiguresReferencesRelatedInformation

Expert Consensus on Perioperative Medications During Endoscopic Submucosal Dissection for Gastric Lesions (2015, Suzhou, China)

Withdrawal: Prospective Randomized Comparison Between Upgraded “2C3L” Versus PVI Approach for Catheter Ablation of Persistent Atrial Fibrillation: PROMPT‐AF Trial Design

An Optimized Integrin Α6‐targeted Peptide for Positron Emission Tomography/magnetic Resonance Imaging of Pancreatic Cancer and Its Precancerous Lesion

Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Single‐center Pilot Trial

Identifying Circulating Glioma Cells and Their Clusters As Diagnostic Markers by a Novel Detection Platform

Detection of Pathogens and Antimicrobial Resistance Genes Directly from Urine Samples in Patients Suspected of Urinary Tract Infection by Metagenomics Nanopore Sequencing: A Large-Scale Multi-Centre Study

UHMK 1 Promotes Gastric Cancer Progression Through Reprogramming Nucleotide Metabolism

Transcriptome-wide Association Analysis Identified Candidate Susceptibility Genes for Nasopharyngeal Carcinoma.

OEM China Water Storage Bladder Tanks OEM/ODM Quotes - Rongda

Outcomes and Toxicities of Immune Checkpoint Inhibitors in Colorectal Cancer: a Real‐world Retrospective Analysis

Human-in-the-loop: Human Involvement in Enhancing Medical Inquiry Performance in Large Language Models

RNA M 6 A Methylation Regulates Sorafenib Resistance in Liver Cancer Through FOXO 3‐mediated Autophagy

Prognostic Significance of Nodular Number in Patients Undergoing Hepatectomy of Intermediate-Stage Hepatocellular Carcinoma.

Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease Guidelines 2017—part 1: Definition, Risk Factors and Assessment

The Monoamine Oxidase-B Inhibitor Selegiline Does Not Affect 18 F-Florzolotau Uptake in Patients with Progressive Supranuclear Palsy: A Longitudinal Case Series.

Reporting Assessment of Multicenter Clinical Trial Protocols: A Cross-Sectional Study

The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease Guidelines 2017—part 2: Management and Special Groups

Long‐term Outcomes of Relapsed/refractory Double‐hit Lymphoma (r/r DHL) Treated with CD19/22 CAR T‐cell Cocktail Therapy

Pan-genome of Cultivated Pepper (capsicum) and Its Use in Gene Presence-Absence Variation Analyses

Persistent Viral Activity, Cytokine Storm, and Lung Fibrosis in a Case of Severe COVID‐19

Cross-Altitude Analysis Suggests A Turning Point at the Elevation of 4,500 M for Polycythemia Prevalence in Tibetans